Related Experiment Video
Updated: Jul 9, 2026

Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
A comparative analysis of select P450 enzymes in uninduced and PB/BNF-induced hamster and rat liver S9
Kristie Evans1, Slaydon Boitnotte1, Errol Zeiger2
1Molecular Toxicology, Inc., 157 Industrial Park Drive, Boone, NC 28607, USA.
Abstract:
The assessment of potentially carcinogenic N-nitrosamine impurities in drugs has become crucial for the pharmaceutical industry to ensure public safety. The in vitro Ames test, which uses rat or hamster liver S9 for metabolic activation, is an important component of regulatory test batteries for assessing mutagenicity and has been the traditional method for assessing the potential mutagenicity of chemicals, including N-nitrosamines. This test, however, has shown inconsistencies with some N-nitrosamines, raising concerns about the liver S9's ability to activate N-nitrosamines to their proximate mutagens. Assays from Vivid® CYP450 Screening Kits and the 7-benzyloxyquinoline assay were used to measure substrate activities of P450 enzymes involved in N-nitrosamine metabolism in rat and hamster liver S9. Both uninduced and induced rat and hamster liver S9 preparations were used. The results provide a comparative assessment of the metabolic competency of the rodent S9s to metabolize N-nitrosamines to their mutagenic forms. Hamster S9 consistently showed increased CYP activity compared to rat S9 under the same conditions. Induced rat S9 also displayed relatively high conversion levels, with the greatest increase in 7-benzyloxyquinoline conversion (CYP3A-like activity) over uninduced (15.7-fold). The highest increase observed with induced hamster S9 was for CYP2A6-like activity which was induced over 7.8-fold and was ∼60-fold higher in induced hamster S9 compared to induced rat S9. These results demonstrate that both rat and hamster S9 contain relevant P450 enzyme activities for N-nitrosamine bioactivation, but hamster S9 is recommended for nitrosamine in vitro tests due to its overall higher P450 activity levels.
Insights
Assessing drug impurities like N-nitrosamines requires reliable mutagenicity tests. Hamster liver S9 shows higher metabolic activity than rat liver S9 for N-nitrosamine bioactivation, making it preferable for in vitro testing.
Area of Science:
- Pharmaceutical Science
- Toxicology
- Drug Safety
Background:
- Ensuring drug safety necessitates evaluating potentially carcinogenic N-nitrosamine impurities.
- The in vitro Ames test, using rodent liver S9 fractions, is standard for assessing mutagenicity but shows inconsistencies with N-nitrosamines.
- Concerns exist regarding the liver S9's capacity to activate N-nitrosamines into their mutagenic forms.
Purpose of the Study:
- To comparatively assess the metabolic competence of rat and hamster liver S9 fractions for N-nitrosamine bioactivation.
- To evaluate the activity of cytochrome P450 (CYP) enzymes involved in N-nitrosamine metabolism in different rodent S9 preparations.
Main Methods:
- Utilized Vivid® CYP450 Screening Kits and the 7-benzyloxyquinoline assay to measure P450 enzyme activities.
- Assessed both uninduced and induced rat and hamster liver S9 preparations.
- Quantified substrate activities relevant to N-nitrosamine metabolism.
Main Results:
- Hamster liver S9 consistently exhibited higher CYP activity than rat liver S9 under identical conditions.
- Induced rat S9 showed significant increases in 7-benzyloxyquinoline conversion (CYP3A-like activity) (15.7-fold).
- Induced hamster S9 demonstrated a substantial increase in CYP2A6-like activity, which was approximately 60-fold higher than in induced rat S9.
Conclusions:
- Both rat and hamster liver S9 fractions possess relevant P450 enzyme activities for N-nitrosamine bioactivation.
- Hamster liver S9 is recommended for in vitro N-nitrosamine testing due to its superior overall P450 activity levels.
- These findings aid in selecting appropriate systems for accurate N-nitrosamine mutagenicity assessments.
More Related Videos
09:33Formation of Covalent DNA Adducts by Enzymatically Activated Carcinogens and Drugs In Vitro and Their Determination by 32P-postlabeling
Published on: March 20, 2018
08:59An Intestine/Liver Microphysiological System for Drug Pharmacokinetic and Toxicological Assessment
Published on: December 3, 2020
Related Concept Videos
Drug Metabolism: Phase I Reactions
Pharmacokinetics in Pediatric Patients: Drug Metabolism
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes